We read with great interest the content-rich Review CYP2D6 and tamoxifen: DNA matters in breast cancer (Nature Rev. Cancer 9, 576-586 (2009)) by Hoskins et al. 1 , which presents the current knowledge on CYP2D6 and tamoxifen in breast cancer. It is thought that CYP2D6 polymorphisms affect CYP2D6 enzyme activity, which further influences the metabolism of tamoxifen as well as the outcome of tamoxifen therapy. The authors concluded that genotype-guided tamoxifen administration might be useful as part of a strategy to optimize the treatment of breast cancer. However, there are two important questions that relate to the CYP2D6 genotype in current research. First, as the authors critically discussed, most studies have not genotyped other non-synonymous alleles except for the CYP2D6*4 allele in the polymorphic CYP2D6 gene [2] [3] [4] . Second, CYP2D6 copy number variations (CNVs) have not been fully considered. In this correspondence, we wish to draw attention to this important area of research on CYP2D6.
Genomic variability is present in many forms, including single nucleotide polymorphisms (SNPs), variable numbers of tandem repeats, copy number alterations and so on 5 . SNPs were previously thought to be the predominant form of genomic variation and to account for most phenotypic variation. More recently, CNVs have been identified and investigated in normal individuals. CYP2D6 is known to be an important tamoxifenmetabolizing gene that is subject to genetic deletion, duplication and multiplication, resulting in varying enzyme activity 6 . Here, we define 'nucleotide polymorphism' as a term representing genetic variation that includes insertion, deletion and replacement of one nucleotide or several nucleotides in CYP2D6. CNV represents a copy number change involving a DNA fragment ≥1 kb. Although the understanding of CNVs is still evolving, it is acknowledged that CNVs result in differential gene expression and account for a substantial proportion of phenotypic variation. For CYP2D6, three or four or more copies have been identified 7   (TABLE 1) . Moreover, CYP2D6 CNV occurs at a high frequency in some populations (TABLE 2) , indicating that the effect of CNVs on CYP2D6 expression is unlikely to be negligible in these populations. Therefore, we propose that, like genotyping CYP2D6 nucleo tide polymorphisms, the determination of CNVs should be evaluated, at least in some populations.
Although many techniques are now available for SNP genotyping, most of them fail to determine CNVs. A reliable and high-throughput test that can identify large-scale gene multiplication or deletion is still unavailable 6 . However, assays such as TaqMan real-time PCR have been developed 8, 9 , and we encourage investigators to examine CNVs of CYP2D6 whenever possible, as the accurate determination of CNVs would warrant true associations between genotypes and phenotypes. For instance, the enzyme CYP2D6*1/*41 (*41 is a common variant associated with decreased enzyme activity 10, 11 and is multiplied in some populations 1, 7 ) is classified as a poor metabolizer. However, it is difficult to determine whether a *41 multiplication (for example, CYP2D6*1/*41 × n, where n≥3) still corresponds to poor activity. Analogously, the description of "multiplication of reduced activity alleles" in We absolutely agree with the authors' statement that large, well-designed clinical trials would support genotype-guided tamoxifen administration. However, ideally one should adopt a genotyping strategy that can decrease, to the greatest extent, genotyping bias. The assessment of CNVs should be carried out in populations with a higher incidence of CNVs in particular, and individuals who are carriers of CYP2D6 multiplication with an unknown level of function should be excluded from clinical trials. 
*Null denotes an allele of CYP2D6 gene deletion (also known as CYP2D6*5). 
